INTRODUCTION {#sec1-1}
============

Combined hyperlipidemia (CHL), a highly atherogenic lipid disorder characterized by increased low-density lipoprotein cholesterol (LDL-C), elevated triglycerides (TGs) and decreased high-density lipoprotein cholesterol (HDL-C) is common in patients with type 2 diabetes mellitus.\[[@ref1]\] Moreover, metabolic abnormalities such as predominance of small dense LDL particles and increased glycation of LDL raise the atherogenic risk in these patients.\[[@ref2][@ref3]\] Glycemic control appears to improve, but does not normalize these abnormalities.\[[@ref4]\]

Cardiovascular disease or coronary artery disease is the major cause of death in both men and women in the developed countries.\[[@ref5]\] Atherosclerosis remains a major risk factor for cardiovascular disease.

Statins or fibrates can be used in this condition. Statins have been shown to reduce atherosclerosis related morbidity and mortality in patients with diabetes mellitus\[[@ref6][@ref7]\] and fibrates can decrease TG concentrations and elevate HDL-C, thus reducing the cardiovascular morbidity and mortality.\[[@ref8][@ref9]\]

Recent studies showed that statin or fibrate monotherapy can improve the lipid profile in patients with type 2 diabetes mellitus.\[[@ref10][@ref11]\] However, these affect different aspects of lipoprotein metabolism. Hence, it is difficult to modify the lipid profile of patients with type 2 diabetes mellitus using the monotherapy with either a statin or a fibrate according to the recent investigations of the American Diabetes Association.\[[@ref12]\]

Hypolipidemic effect of atorvastatin is due to inhibition of hydroxymethylglutaryl-CoA reductase and decrease in LDL-C is also due to up regulation of LDL receptor activity.\[[@ref13]\] Outcome trials of statins have proved conclusively that these classes of drugs decrease LDL-C levels, resulting in a significant reduction of cardiovascular events in many high-risk patients.\[[@ref14][@ref15]\] It has been shown that statins significantly reduced circulating levels of all major LDL subspecies; light, intermediate and dense.\[[@ref16]\] Statins have been reported to produce "pleiotropic" effects such as vasodilatation, plaque stabilization, antioxidant, anti-inflammatory and antithrombotic effects.\[[@ref17]\]

Fibrates, commonly referred to as peroxisome proliferator activated receptor-α (PPAR-α) agonists, are subfamily of the nuclear receptor superfamily that have been noted to be naturally activated by ligands such as free fatty acids and eicosanoids.\[[@ref18][@ref19][@ref20]\] PPAR-α expression is present in liver, kidney, endothelium and vascular smooth muscle. They significantly decrease TG levels, LDL-C and increase HDL-C and hence help in reducing the cardiovascular events.\[[@ref21]\] Fibrates decrease the production of TG-rich lipoproteins and increase the catabolism of TGs by the inducing lipoprotein lipase and also reduces expression of apolipoprotein C-III through activation of PPAR-α.

An effective therapeutic approach for CHL is a combination of statin and fibrate.\[[@ref22][@ref23][@ref24][@ref25][@ref26]\] Studies comparing lipid lowering therapies have shown that atorvastatin reduces all LDL sub fractions, whereas fenofibrate reduces LDL density. This is due to a more pronounced reduction of the densest LDL fraction (LDL-6) by fenofibrate compared with atorvastatin. The literature on statin-fibrate combinations in patients with type 2 diabetes and CHL is limited. Hence, an open label, prospective, randomized, parallel study was undertaken to investigate the hypothesis that combination therapy with atorvastatin and fenofibrate will be more effective than monotherapy with a statin/fibrate to prevent coronary heart disease in patients with type 2 diabetes mellitus.

MATERIALS AND METHODS {#sec1-2}
=====================

Study Design {#sec2-1}
------------

An open-labeled, randomized, prospective study was conducted from March 2009 to June 2010 in patients of type 2 diabetes mellitus associated with hyperlipidemia, attending the out-patient Department of Endocrinology, Sri Venkateswara Institute of Medical Sciences, Tirupati. The study was conducted by the Department of Pharmacology, Sri Venkateswara Medical College, Tirupati.

Patients of either gender in the age group of 30-70 years diagnosed as type 2 diabetes mellitus with hyperlipidemia (total cholesterol \[TC\] \>200 mg/dl, TGs \> 150 mg/dl, LDL-C \>100 mg/dl, HDL-C \< 40 mg/ dl) based on criteria laid down by National Cholesterol Education Program (NCEP Adult Treatment Panel III) guidelines were included in the study. Only newly diagnosed hyperlipidemic patients of diabetes mellitus were included in the study.

Patients on concurrent therapy with beta blockers, thiazides, oral contraceptives pills, and cyclosporine, erythromycin and azole antifungals were excluded. Patients having liver dysfunction (levels of transaminases 1.5 or more times the upper limit of normal, renal dysfunction (serum creatinine greater than 1.6 mg/dl) and pregnant and lactating women were also excluded from the study.

The Institutional Ethical Committee approved the study protocol and informed consent was obtained from all patients before enrollment after detailed explanation of possible adverse effects of the drug combinations.

Patients were on the National Cholesterol Expert Panel step 1 hypolipedemic diet, which limits dietary intake of cholesterol to 300 mg/day, saturated fats 10% of total energy intake and total fats to 30% total energy intake during the study. Anti-diabetic drugs used remained unchanged throughout the study.

Patients who fulfilled the inclusion/exclusion criteria were randomly divided into two groups of 30 each by simple randomization using computer generated random numbers. All laboratory investigations were obtained after the patients had fasted for 12 h overnight and included the estimation of serum lipid parameters (TC, HDL-C, LDL-C,TGs and VLDL-C) as well as fasting blood sugar (FBS), glycated hemoglobin (HbA~1c~), Hb%, renal function tests and liver function tests were measured during screening in the same laboratory. Baseline characteristics of the study population are listed in [Table 1](#T1){ref-type="table"}.

###### 

Patient demographic and baseline characteristics
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Treatment Schedule {#sec2-2}
------------------

Group 1 received atorvastatin 10 mg/day and Group 2 received combination of atorvastatin 10 mg/day and fenofibrate 145 mg/day for 12 weeks orally at night. All patients purchased the drugs from the hospital pharmacy as per prescription. Patients were assessed after 12 weeks and were asked to report immediately if they developed unusual muscle soreness or pain throughout the study. Lipid profile, FBS was done after 12 weeks. In case of history of muscle pain, creatine phospho kinase was also evaluated at the end of the study.

Serum cholesterol and TGs were determined using an enzymatic colorimetric assay and HDL-C was determined by phosphotungstic acid method. LDL-C was calculated using Friedewald\'s formula (LDL = TC - \[TG/5 + HDL\]).

Sample Size Calculation and Statistical Analysis {#sec2-3}
------------------------------------------------

Sample size was calculated taking into consideration the mean values and standard deviation from the study done by Athyro *et al*.\[[@ref27]\] Power of the study = 90%, α = 0.05 and β = 0.1. The data obtained were analyzed using descriptive statistics and paired and unpaired Student t-test to compare results within the group and between groups.

RESULTS {#sec1-3}
=======

From the initial 30 patients in Group 2, one patient terminated the study for personal reasons and one patient interrupted the study because of mild muscle pain. Thus, 58 patients completed the study. They received atorvastatin (*n* = 30) and combination of atorvastatin and fenofibrate (*n* = 28) for a period of 3 months. These patients tolerated both study medications well and completed the study. No significant adverse events were recorded during the study.

Changes in the Lipid Profile {#sec2-4}
----------------------------

There was a significant reduction (*P* \< 0.001) in TC (28%), TGs (20%), LDL-C (37%), VLDL-C (20%) and insignificant increase in HDL-C in atorvastatin group at the end of 3 months as compared to pretreatment values. There was a significant reduction (*P* \< 0.001) in TC (31%), TGs (39%), LDL-C (33%), VLDL-C (40%) and insignificant decrease in HDL-C in combination treatment group at the end of 3 months as compared with pretreatment values as represented in [Table 2](#T2){ref-type="table"}.

###### 

Comparison of changes in the lipid profile between the two treatment groups after 12 weeks
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The reduction in TC, TGs, VLDL-C in combination treatment group was statistically significant (*P* \< 0.001) when compared to atorvastatin group alone. The observed difference in a decrease in LDL-C and change in HDL-C was not statistically significant between the two treatment groups \[[Table 2](#T2){ref-type="table"}\].

DISCUSSION {#sec1-4}
==========

Type 2 diabetes mellitus is one of the most common chronic disease and is associated with co-morbidities such as obesity, hypertension, hyperlipidemia and cardiovascular disease, which together, constitute metabolic syndrome.\[[@ref28]\]

There is evidence to suggest that diabetes is more common in females than males. In recent years an increase in number of diabetic males resulted in an equal prevalence rates for both males and females in some societies.\[[@ref29]\]

In our study, we have analyzed the effect of atorvastatin 10 mg once daily and combination of atorvastatin 10 mg and fenofibrate 145 mg once daily in type 2 diabetes mellitus patients associated with hyperlipidemia. Patients were in the age group of 30-70 years in both groups. Both treatments had decreased TC, TG, LDL-C, VLDL-C, but the reduction of TC, TG, VLDL-C was more and statistically significant in combination treatment group when compared with atorvastatin group alone at the end of 12 weeks. The observed difference in decrease in LDL-C and change in HDL-C was not statistically significant between the two treatment groups.

A similar study, which compared the effect of atorvastatin (20 mg/day) alone with micronized fenofibrate (200 mg/day) monotherapy and in combination with fenofibrate in type 2 diabetes mellitus patients with CHL where in the patients were in the age group of 44-69 years.\[[@ref27]\] The combination treatment had reduced TC by 37%, LDL-C by 46%, TGs by 50% and increased HDL-C by 46% (*P* \< 0.0001 for all) and these changes were significantly better than those of monotherapy. No significant adverse events were recorded during the study.

In another study, combination of simvastatin (20 mg/day)and bezafi brate (400 mg/day) had reduced TC by 23% and LDL-C by 29% but had significantly reduced TG levels by 42% and increased HDL-C by 25%. Of the 148 patients from this study, 2 had presented with myopathy.\[[@ref30]\]

In Action to Control Cardiovascular Risk in Diabetes lipid trial it was found that combination therapy with the use of fenofibrate and simvastatin (at a daily dose of 40 mg or less) did not reduce rates of cardiovascular disease as compared with simvastatin alone.\[[@ref31]\]

The primary risk of using statins in combination with fibrates is believed to be hepatotoxicity and myopathy.\[[@ref25]\] In most studies combination therapy was no more hepatotoxic than the statin itself.\[[@ref32]\] However, due to limited number of patients and the short term follow-up, we cannot draw any definite conclusions. Hence, further studies in a large number of patients and for longer duration are necessary to assess the long-term safety of this combination.

**Source of Support:** Nil

**Conflict of Interest:** Nil.
